Knocking down of HDAC1 has been reported to enhance the sensitivity to cisplatin-based chemotherapy in ovarian cancer (Liu et al., 2018), indicating that HDAC1 is a potential therapeutic target. Here, HDAC1 is linked to ovarian carcinoma.